Trials / Completed
CompletedNCT00912860
Immunogenicity and Safety Study of Serum-Free Avonex
A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 155 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon beta-1a | serum free Avonex given IM once a week |
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2004-12-01
- Completion
- 2005-01-01
- First posted
- 2009-06-03
- Last updated
- 2009-06-10
Source: ClinicalTrials.gov record NCT00912860. Inclusion in this directory is not an endorsement.